Tramadol Hydrochloride + Placebo
Phase 3Terminated 0 watching 0 views this weekπ Rising
72
Development Stage
β
Pre-clinicalβ
Phase 1β
Phase 24
Phase 35
ApprovedIndication / Disease
Premature Ejaculation
Conditions
Premature Ejaculation
Trial Timeline
Oct 1, 2009 β Sep 1, 2010
NCT ID
NCT00983736About Tramadol Hydrochloride + Placebo
Tramadol Hydrochloride + Placebo is a phase 3 stage product being developed by Bausch Health for Premature Ejaculation. The current trial status is terminated. This product is registered under clinical trial identifier NCT00983736. Target conditions include Premature Ejaculation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00983736 | Phase 3 | Terminated |
Competing Products
8 competing products in Premature Ejaculation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| dapoxetine | Yuhan | Phase 1/2 | 41 |
| PSD502, contains a mixture of lidocaine and prilocaine + Placebo | Shionogi | Phase 2/3 | 65 |
| Placebo + Cisapride | Johnson & Johnson | Approved | 85 |
| SHR7280οΌGanirelix Acetate Injection simulant + SHR7280 simulantοΌ Ganirelix Acetate Injection | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| ranolazine | Gilead Sciences | Phase 2 | 51 |
| IX-01 + Placebo | ICON plc. | Phase 2 | 49 |
| Flecainide (monotherapy) | Brain Biotech | Pre-clinical | 15 |
| Tramadol Hydrochloride & Placebo | Bausch Health | Phase 3 | 72 |